CA2795164C - Antagonists of mirna-29 expression and their use in the prevention and treatment of aortic aneurysms - Google Patents
Antagonists of mirna-29 expression and their use in the prevention and treatment of aortic aneurysms Download PDFInfo
- Publication number
- CA2795164C CA2795164C CA2795164A CA2795164A CA2795164C CA 2795164 C CA2795164 C CA 2795164C CA 2795164 A CA2795164 A CA 2795164A CA 2795164 A CA2795164 A CA 2795164A CA 2795164 C CA2795164 C CA 2795164C
- Authority
- CA
- Canada
- Prior art keywords
- mirna
- antisense
- antisense oligonucleotide
- aortic aneurysm
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007474 aortic aneurysm Diseases 0.000 title claims abstract description 66
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 230000014509 gene expression Effects 0.000 title abstract description 56
- 239000005557 antagonist Substances 0.000 title abstract description 41
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 41
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 41
- 108091034117 Oligonucleotide Proteins 0.000 claims description 32
- 108700000163 miRNA-29b Proteins 0.000 claims description 25
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 9
- -1 COL1A3 Proteins 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 102100031509 Fibrillin-1 Human genes 0.000 claims description 5
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 claims description 5
- 230000003828 downregulation Effects 0.000 claims description 5
- 206010060874 Aortic rupture Diseases 0.000 claims description 4
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 4
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 4
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003313 weakening effect Effects 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002679 microRNA Substances 0.000 abstract description 55
- 108091070501 miRNA Proteins 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 14
- 108700011259 MicroRNAs Proteins 0.000 description 38
- 210000000709 aorta Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 108091029162 miR-29 stem-loop Proteins 0.000 description 8
- 206010002329 Aneurysm Diseases 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108060002895 fibrillin Proteins 0.000 description 5
- 102000013370 fibrillin Human genes 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960004586 rosiglitazone Drugs 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 102100033167 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 208000021654 bicuspid aortic valve disease Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 108091028606 miR-1 stem-loop Proteins 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000026799 smooth muscle cell apoptotic process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010057453 Aortic dilatation Diseases 0.000 description 1
- 101100328883 Arabidopsis thaliana COL1 gene Proteins 0.000 description 1
- 206010004552 Bicuspid aortic valve Diseases 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 108091067741 Mus musculus miR-129-1 stem-loop Proteins 0.000 description 1
- 108091066266 Mus musculus miR-129-2 stem-loop Proteins 0.000 description 1
- 108091068693 Mus musculus miR-136 stem-loop Proteins 0.000 description 1
- 108091068690 Mus musculus miR-140 stem-loop Proteins 0.000 description 1
- 108091068662 Mus musculus miR-154 stem-loop Proteins 0.000 description 1
- 108091067719 Mus musculus miR-182 stem-loop Proteins 0.000 description 1
- 108091067718 Mus musculus miR-183 stem-loop Proteins 0.000 description 1
- 108091067727 Mus musculus miR-186 stem-loop Proteins 0.000 description 1
- 108091065439 Mus musculus miR-223 stem-loop Proteins 0.000 description 1
- 108091066252 Mus musculus miR-31 stem-loop Proteins 0.000 description 1
- 108091066219 Mus musculus miR-322 stem-loop Proteins 0.000 description 1
- 108091066052 Mus musculus miR-329 stem-loop Proteins 0.000 description 1
- 108091066064 Mus musculus miR-337 stem-loop Proteins 0.000 description 1
- 108091067517 Mus musculus miR-377 stem-loop Proteins 0.000 description 1
- 108091067537 Mus musculus miR-379 stem-loop Proteins 0.000 description 1
- 108091033115 Mus musculus miR-411 stem-loop Proteins 0.000 description 1
- 108091032021 Mus musculus miR-434 stem-loop Proteins 0.000 description 1
- 108091028840 Mus musculus miR-758 stem-loop Proteins 0.000 description 1
- 108091066264 Mus musculus miR-98 stem-loop Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003843 furanosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091007432 miR-29b Proteins 0.000 description 1
- 108091048549 miR-29b stem-loop Proteins 0.000 description 1
- 108091047189 miR-29c stem-loop Proteins 0.000 description 1
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003675.5 | 2010-04-01 | ||
| EP10003675A EP2371370A1 (en) | 2010-04-01 | 2010-04-01 | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
| PCT/EP2011/055122 WO2011121120A1 (en) | 2010-04-01 | 2011-04-01 | ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2795164A1 CA2795164A1 (en) | 2011-10-06 |
| CA2795164C true CA2795164C (en) | 2019-06-18 |
Family
ID=42269707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795164A Active CA2795164C (en) | 2010-04-01 | 2011-04-01 | Antagonists of mirna-29 expression and their use in the prevention and treatment of aortic aneurysms |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062307B2 (enExample) |
| EP (2) | EP2371370A1 (enExample) |
| JP (2) | JP6224455B2 (enExample) |
| CN (1) | CN102939090A (enExample) |
| AU (1) | AU2011234453B2 (enExample) |
| CA (1) | CA2795164C (enExample) |
| ES (1) | ES2690198T3 (enExample) |
| RU (1) | RU2012146518A (enExample) |
| WO (1) | WO2011121120A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US8618073B2 (en) | 2010-07-22 | 2013-12-31 | The University Of North Carolina At Chapel Hill | Use of miR-29 for cell protection |
| JP2015518475A (ja) * | 2012-04-10 | 2015-07-02 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 非アルコール性脂肪性肝炎の治療方法 |
| EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
| US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| RU2712511C2 (ru) * | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
| US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2017214949A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219169A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| CN109762883B (zh) * | 2019-01-31 | 2020-01-21 | 温州医科大学 | 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用 |
| CN110511930B (zh) * | 2019-06-11 | 2023-01-10 | 河北医科大学 | Sal-miR-58及其在抑制血管炎性反应和动脉瘤形成中的用途 |
| CN117979975A (zh) * | 2021-05-07 | 2024-05-03 | 加利福尼亚大学董事会 | 用于预防和治疗动脉瘤、高血压、ards和其他与内皮功能障碍相关联的疾病的mirna抑制剂 |
| US20250304956A1 (en) * | 2021-08-06 | 2025-10-02 | Leadermed Champion Limited | miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
| CN114432453B (zh) * | 2022-02-25 | 2022-10-14 | 上海大学 | 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| ES2621161T3 (es) | 2007-07-31 | 2017-07-03 | The Board Of Regents Of The University Of Texas System | Familia de micro-ARN que modula la fibrosis y usos de la misma |
| CL2008003699A1 (es) * | 2007-12-13 | 2009-10-09 | Takeda Pharmaceuticals Co | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. |
| CA2716343A1 (en) * | 2008-02-21 | 2009-08-27 | The Board Of Regents Of The University Of Texas System | Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof |
-
2010
- 2010-04-01 EP EP10003675A patent/EP2371370A1/en not_active Withdrawn
-
2011
- 2011-04-01 JP JP2013501865A patent/JP6224455B2/ja active Active
- 2011-04-01 AU AU2011234453A patent/AU2011234453B2/en active Active
- 2011-04-01 WO PCT/EP2011/055122 patent/WO2011121120A1/en not_active Ceased
- 2011-04-01 EP EP11711597.2A patent/EP2552454B1/en active Active
- 2011-04-01 RU RU2012146518/15A patent/RU2012146518A/ru not_active Application Discontinuation
- 2011-04-01 CN CN2011800172888A patent/CN102939090A/zh active Pending
- 2011-04-01 CA CA2795164A patent/CA2795164C/en active Active
- 2011-04-01 US US13/637,924 patent/US9062307B2/en active Active
- 2011-04-01 ES ES11711597.2T patent/ES2690198T3/es active Active
-
2016
- 2016-03-24 JP JP2016060073A patent/JP2016193888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9062307B2 (en) | 2015-06-23 |
| CN102939090A (zh) | 2013-02-20 |
| EP2552454A1 (en) | 2013-02-06 |
| US20130116303A1 (en) | 2013-05-09 |
| ES2690198T3 (es) | 2018-11-19 |
| CA2795164A1 (en) | 2011-10-06 |
| JP6224455B2 (ja) | 2017-11-01 |
| EP2371370A1 (en) | 2011-10-05 |
| RU2012146518A (ru) | 2014-05-10 |
| JP2016193888A (ja) | 2016-11-17 |
| EP2552454B1 (en) | 2018-07-11 |
| AU2011234453A1 (en) | 2012-10-18 |
| WO2011121120A1 (en) | 2011-10-06 |
| JP2013523696A (ja) | 2013-06-17 |
| AU2011234453B2 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2795164C (en) | Antagonists of mirna-29 expression and their use in the prevention and treatment of aortic aneurysms | |
| Grimaldi et al. | Evidence of epigenetic tags in cardiac fibrosis | |
| KR101706259B1 (ko) | 섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도 | |
| JP5898843B2 (ja) | 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法 | |
| Piccoli et al. | Non-coding RNAs as modulators of the cardiac fibroblast phenotype | |
| US20110293674A1 (en) | MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION | |
| US9388411B2 (en) | miRNA-212/132 family as a therapeutic target | |
| WO2010103015A1 (en) | Microrna for diagnostic and therapeutic purposes in cardiovascular diseases | |
| WO2010120969A1 (en) | Targeting of the mir-30 family and let-7 family as a treatment for heart disease | |
| CN112839664A (zh) | 瘢痕疙瘩或者增生性瘢痕预防或者治疗用组合物 | |
| JP2013511964A (ja) | ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| Guedes et al. | High fat diet reduces the expression of miRNA‐29b in heart and increases susceptibility of myocardium to ischemia/reperfusion injury | |
| EP3329004B1 (en) | Therapeutic oligonucleotides | |
| Latsios et al. | MicroRNAs in the diagnosis and treatment of unstable angina | |
| CN102266569B (zh) | miR-199a及其抑制剂的应用 | |
| WO2013068600A1 (en) | Medicament for the treatment of cardiac disease | |
| Preethi et al. | Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications | |
| WO2015055858A2 (en) | Vascular re-modelling | |
| KR20150078074A (ko) | microRNA-365 활성화제를 포함하는 혈관평활근세포 증식 또는 이동 억제용 약학적 조성물 | |
| WO2018024878A1 (en) | Methods and compositions for reducing pcsk9 expression | |
| EP4662317A1 (en) | Pharmaceutical composition for use in treatment of venous thromboembolism | |
| EP3546578A1 (en) | Ap-1 binding polynucleotides | |
| Tang | Novel mechanisms regulating vascular smooth muscle proliferation and differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160309 |